Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2
NCT ID: NCT03220399
Last Updated: 2019-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1
INTERVENTIONAL
2019-12-01
2020-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetic Characteristics and Safety After Administration of NVP-2002
NCT04961905
Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2
NCT03802526
The Food Effect on the Pharmacokinetics of NVP-1402
NCT03340480
Pharmacokinetics of BPDO-1603 or BPDO-16031 and BPDO-16033 Administration in Healthy Adults
NCT05804279
Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers
NCT03565861
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NVP-1603-1 (P)
Drug: NVP-1603-1
1capsule, oral dosing
NVP-1603-1 (P)
1capsule, single oral dosing
NVP-1603-2(T)
Drug: NVP-1603-2
1Tablet, oral dosing
NVP-1603-2 (T)
1tablet, single oral dosing
NVP-1603-1and NVP-1603-2 (P+T)
Drug: NVP-1603-1, 1capsule and NVP-1603-2, 1Tablet co-adminstration (oral dosing)
NVP-1603-1 and NVP-1603-2 (P+T)
1capsule and 1tablet co-administration, oral single dosing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NVP-1603-1 (P)
1capsule, single oral dosing
NVP-1603-2 (T)
1tablet, single oral dosing
NVP-1603-1 and NVP-1603-2 (P+T)
1capsule and 1tablet co-administration, oral single dosing
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI of \>18.5kg/㎡ and \<27.0kg/㎡ subject, weight more than 50kg.
* Subject has signed and dated informed consent.
Exclusion Criteria
* History of (or presence) study medication absortion, distribution, metabolism(e.g., liver/ductal, kidney, cardio-vascular, endocrine, respiratory, GI, hematology, oncology, CNS, musculo-skeletal) or related past medical/surgery history
* Current alcohol abuse.
19 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NVP Healthcare
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NVP-1603_P1_DDI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.